As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/03/11  Nymox Pharmaceutical Corp         20-F/A     12/31/10    7:474K                                   e3 Fil… Computershare/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F/A      Annual Report for the Fiscal Year Ended December    HTML     23K 
                          31, 2010 - Amendment No. 1                             
 2: EX-4.S      Common Stock Private Purchase Agreement Dated       HTML    103K 
                          November 1, 2010                                       
 3: EX-4.T      License and Collaboration Agreement Dated December  HTML    336K 
                          16, 2010                                               
 4: EX-12.A     Sox Section 302 CEO Certification                   HTML     10K 
 5: EX-12.B     Sox Section 302 CFO Certification                   HTML     10K 
 6: EX-13.A     Sox Section 906 CEO Certification                   HTML      7K 
 7: EX-13.B     Sox Section 906 CFO Certification                   HTML      7K 

 

[   ] Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934

or

[ X ] Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

For the fiscal year ended December 31, 2010

or

[   ] Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

or

[   ] Shell Corporation Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number: 001-12033

 

 

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Securities registered or to be registered pursuant to Section 12(g) of the Act

None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act

None

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report.

32,573,856 shares as of December 31, 2010

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes [   ] No [ X ]

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Yes [   ] No [ X ]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [ X ] No [   ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website; if any, every interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232-405 of this chapter) during the preceding twelve months (or for such shorter period that the registrant was required to submit and post such files).

Yes [   ] No [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [   ] Accelerated filer [ X ] Non-accelerated filer [   ]

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:

Item 17 [   ] Item 18 [ X ]

If this is an annual report, indicate by check mark whether the registrant is a shell Company (as defined in Rule 12b-2 of the Exchange Act).

Yes [   ] No [ X ]

EXPLANATORY NOTE

This Form 20-F/A is being filed by Nymox Pharmaceutical Corporation as Amendment No. 1 to its Annual Report on Form 20-F for the fiscal year ended December 31, 2010, as originally filed with the Securities and Exchange Commission on March 15, 2011 (the “Original 2010 20-F” and, as amended by this Amendment No. 1, the “2010 20-F”), to amend the Original 2010 20-F to correct an administrative error by attaching Exhibits 4(s) and 4(t) thereto as separate exhibits to the 2010 20-F, rather than as a part of the main body thereof.

We are including in this Amendment No. 1 currently dated certifications by our principal executive officer and our principal financial officer. Other than as expressly set forth above, this Amendment No. 1 does not, and does not purport to, amend, update or restate the information in any other item of the Original 2010 20-F, or reflect any events that have occurred after the Original 2010 Form 20-F was originally filed.

ITEM 19. EXHIBITS

The following exhibits are included with or incorporated by reference into this report:

 

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

 

Date: June 3, 2011

 

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/02/23  Nymox Pharmaceutical Corp.        20-F       12/31/22  105:5.5M                                   Pubco Reporting … Inc/FA
 3/30/22  Nymox Pharmaceutical Corp.        20-F       12/31/21  106:6M                                     Pubco Reporting … Inc/FA
 3/29/21  Nymox Pharmaceutical Corp.        20-F       12/31/20  103:4.4M                                   Pubco Reporting … Inc/FA